SK Bioscience Co.,Ltd Logo

SK Bioscience Co.,Ltd

A global biotech firm developing vaccines for diseases like COVID-19, influenza, and shingles.

302440 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로 310, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SK Bioscience is a global vaccine and biotechnology company dedicated to promoting human health through the research, development, and manufacturing of vaccines. Spun off from SK Chemicals in 2018, the company utilizes advanced platforms, including cell culture and recombinant protein technologies. Its portfolio of proprietary products includes SKYCovione™ (COVID-19), SKYCellflu® (the world's first cell-cultured quadrivalent influenza vaccine), SKY Zoster® (shingles), and SKY Varicella® (chickenpox). SK Bioscience actively expands its global presence through strategic collaborations with international partners and health organizations, such as the Bill & Melinda Gates Foundation, embodying its mission 'From Prevention To Cure'.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for SK Bioscience Co.,Ltd and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등거래계획보고서
Korean 47.1 KB
2025-09-19 00:00
Related Party Transaction
특수관계인에대한부동산매도
Korean 5.2 KB
2025-09-19 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 92.4 KB
2025-08-29 00:00
Governance Information
대규모기업집단현황공시[분기별공시(개별회사용)]
Korean 7.9 KB
2025-08-13 00:00
Regulatory News Service
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Korean 11.0 KB
2025-08-12 00:00
Interim Report
반기보고서 (2025.06)
Korean 4.3 MB
2025-07-31 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 15.0 KB
2025-07-31 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.1 KB
2025-07-21 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.1 KB

Automate Your Workflow. Get a real-time feed of all SK Bioscience Co.,Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SK Bioscience Co.,Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Tego Science, Inc. Logo
Develops cell therapies for skin regeneration, 3D models for testing, and provides CDMO services.
South Korea 191420
Teva Pharmaceutical Industries Ltd. Logo
A leader in affordable generic drugs and innovative specialty treatments for complex diseases.
Israel TEVA
THERAGEN ETEX CO.,LTD. Logo
A biotech firm offering gene analysis and developing personalized cancer drugs.
South Korea 066700
TheraVet SA Logo Belgium ALVET
Thor Medical ASA Logo
Sustainably produces alpha-emitters from thorium for cancer therapies, without nuclear reactors.
Norway NANOV
Tikun Olam Cannbit Pharmaceuticals Ltd. Logo
A vertically integrated pharma company developing research-backed, EU-GMP medical cannabis products.
Israel TKUN
TiumBio Co., Ltd. Logo
Clinical-stage biopharma developing therapies for rare diseases, gynecology, and hemophilia.
South Korea 321550
TMS Co., Ltd Logo
Develops small molecule drugs from natural compounds for the global pharmaceutical market.
Japan 4891
Together Pharma Ltd. Logo
Researches and produces medical cannabis products for domestic and European patients.
Israel TGTR
A pharmaceutical specialist in drugs for renal, skin, and allergic diseases.
Japan 4551

Talk to a Data Expert

Have a question? We'll get back to you promptly.